Astria Therapeutics Announces New Stock Option Grants as Part of 2022 Inducement Stock Incentive Plan

Reuters
04 Jun
Astria <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces New Stock Option Grants as Part of 2022 Inducement Stock Incentive Plan

Astria Therapeutics Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has announced the issuance of stock options under its 2022 Inducement Stock Incentive Plan. On June 2, 2025, the company granted options to purchase 62,000 shares of its common stock to two new employees as an inducement for joining the company. The options carry an exercise price of $4.78, matching the closing stock price on the grant date, and are scheduled to vest over four years. Initially, 25% of the shares will vest on the first anniversary of the employees' start date, with the remainder vesting monthly over the subsequent 36 months, contingent upon continued employment with Astria. These options are governed by the terms of the 2022 Inducement Stock Incentive Plan and specific award agreements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250603388391) on June 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10